公开(公告)号：US20170327497A1

公开(公告)日：2017-11-16

申请号：US15599337

申请日：2017-05-18

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Mark E. Adams ,  Rongliang Chen ,  Betty Lam ,  Matthew Lardy ,  Srinivasa Reddy Natala ,  Steven James Wilkens ,  Mitsunori Kono ,  Zhe Nie

IPC: C07D471/04 ,  C07D498/04 ,  C07D495/04 ,  C07D487/04 ,  A61K31/5383 ,  A61K31/5365 ,  A61K31/519 ,  A61K31/4985 ,  A61K31/437 ,  C07D519/00 ,  A61K31/4365

CPC classification number: C07D471/04 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5365 ,  A61K31/5383 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D519/00

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, p, R1, R2, R3a, R4, and R5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

公开(公告)号：US20150274723A1

公开(公告)日：2015-10-01

申请号：US14706876

申请日：2015-05-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Mark E. Adams ,  Rongliang Chen ,  Betty Lam ,  Matthew Lardy ,  Srinivasa Reddy Natala ,  Steven James Wilkens ,  Mitsunori Kono ,  Zhe Nie

IPC: C07D471/04 ,  A61K31/519 ,  A61K31/5365 ,  A61K31/4985 ,  A61K31/437 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5365 ,  A61K31/5383 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D519/00

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, p, R1, R2, R3a, R4, and R5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中G，p，R1，R2，R3a，R4和R5在说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗涉及免疫系统和炎症的疾病，疾病和病症的用途，包括类风湿性关节炎，癌症和其它疾病 ，疾病和表示SYK抑制的病症。